Search Results - "Kent, G.N"

Sequestosome 1 mutations in Paget's disease of bone in Australia: Prevalence, genotype/phenotype correlation and a novel non-UBA domain mutation (P364S) associated with increased NF-κB signalling without loss of ubiquitin-binding by Rea, S.L, Walsh, J.P, Ward, L, Magno, A.L, Ward, B.K, Shaw, B, Layfield, R, Kent, G.N, Xu, J, Ratajczak, T

Get full text

A positive rheumatoid factor and X-ray damage predict focal and generalized bone loss in patients with mild rheumatoid arthritis followed over two years by Zhou, Huiqiong, Yao, Ruyu, Wilson, H, Song, S, Breidahl, B, Roff, G, Kent, G.N, Will, R.K

Get full text

Biphasic effect of calcitonin on tartrate‐resistant acid phosphatase activity in isolated rat osteoclasts by Yumita, S., Nicholson, G.C., Rowe, D.J., Kent, G.N., Martin, T.J.

“…Tartrate‐resistant acid phosphatase (TRAP) has been implicated as being involved in osteoclastic bone resorption, and calcitonin (CT) is known to inhibit the…”
Get full text

The degradation of proparathormone and parathormone by [porcine] parathyroid and liver cathepsin B by MacGregor, R.R, Hamilton, J.W, Kent, G.N, Shofstall, R.E, Cohn, D.V

“…Purified cathepsin B from porcine parathyroid glands was allowed to act upon radioactive bovine parathormone and proparathormone at various ratios of enzyme to…”
Get full text

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone by Walsh, J.P, Ward, L.C, Stewart, G.O, Will, R.K, Criddle, R.A, Prince, R.L, Stuckey, B.G.A, Dhaliwal, S.S, Bhagat, C.I, Retallack, R.W, Kent, G.N, Drury, P.J, Vasikaran, S, Gutteridge, D.H

“…Second and third generation bisphosphonates are the treatment of choice for Paget’s disease of bone. These drugs are more effective than calcitonin and…”
Get full text

Comparison of biochemical markers of bone turnover in paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross‐links by Randall, A.G., Kent, G.N., Garcia‐Webb, P., Bhagat, C.I., Pearce, D.J., Gutteridge, D.H., Prince, R.L., Stewart, G., Stuckey, B., Will, R.K., Retallack, R.W., Price, R.I., Ward, L.

“…We have compared the use of new markers of bone turnover in the assessment and treatment of Paget disease and made observations on the mechanisms of bone…”
Get full text

Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another by Gutteridge, D.H., Ward, L.C., Stewart, G.O., Retallack, R.W., Will, R.K., Prince, R.L., Criddle, A., Bhagat, C.I., Stuckey, B.G.A., Price, R.I., Kent, G.N., Faulkner, D.L., Geelhoed, E., Gan, S.K., Vasikaran, S.

“…Twenty‐five years after the first paper on etidronate in Paget's disease, there are few published papers that address bisphosphonate resistance as a specific…”
Get full text

Bone density changes in Paget’s disease 2 years after iv pamidronate: profound, sustained increases in pagetic bone with severity-related loss in forearm nonpagetic cortical bone by Gutteridge, D.H, Retallack, R.W, Ward, L.C, Price, R.I, Stewart, G.O, Stuckey, B.G.A, Prince, R.L, Kent, G.N, Bhagat, C.I, Thompson, R.I, Nicholson, G.C

“…Bone mineral density (BMD) was measured at three sites (forearm, spine, and hip) using dual X-ray and single-photon absorptiometry in 68 patients with Paget’s…”
Get full text

Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2-year study by Gutteridge, D.H., Retallack, R.W., Ward, L.C., Stuckey, B.G.A., Stewart, G.O., Prince, R.L., Kent, G.N., Bhagat, C.I., Price, R.I., Thompson, R.I., Nicholson, G.C.

“…An intravenous dosage schedule using pamidronate disodium, based on biochemical severity, was used to treat 71 patients with Paget's disease who had had no…”
Get full text

A randomized treatment trial of intravenous pamidronate and oral alendronate in Paget’s disease: early results by Gutteridge, D.H, Ward, L.C, Stewart, G.O, Retallack, R.W, Prince, R.L, Bhagat, C.I, Stuckey, B.G.A, Will, R.K, Kent, G.N, Price, R.I, Gan, S.K

Get full text

Prevention of appendicular bone loss in Paget’s disease following treatment with intravenous pamidronate disodium by Stewart, G.O, Gutteridge, D.H, Price, R.I, Ward, L, Retallack, R.W, Prince, R.L, Stuckey, B.G.A, Kent, G.N, Bhagat, C.I, Dhaliwal, S.S

“…It has been shown previously that intravenous pamidronate treatment for severe Paget’s disease is associated with appendicular bone loss. This 2 year study was…”
Get full text

Intravenous pamidronate in Paget's disease--response is dependent on radiographic and biochemical severity by Stuckey, B G, Gutteridge, D H, Stewart, G O, Prince, R L, Ward, L C, Kent, G N, Prince, R I, Retallack, R W, Bhagat, C I, Nicholson, G C

Get more information

Radioimmunoassay of the basal circulating level of calcitonin in the rat by Kent, G N, Retallack, R W

Get more information